News

rarediseaseadvisor23d
Rituximab Can Achieve Remission in Steroid-Refractory Disease
More standardized research is needed to guide second-line agent selection in IgG4-RD. Rituximab offers a highly effective steroid-sparing option for the treatment of immunoglobulin G4-related disease ...
Investing1mon
FDA approves Uplizna as first IgG4-RD targeted therapy
IgG4-RD is a rare, chronic inflammatory condition that can lead to fibrosis and organ damage. The approval is based on the results of the MITIGATE trial, which showed an 87% reduction in the risk ...
PR Newswire1mon
FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market Opportunity in Rare Autoimmune Segment | DelveInsight
The drug has become the first to receive FDA approval specifically for treating immunoglobulin G4-related disease (IgG4-RD). LAS VEGAS, April 14, 2025 /PRNewswire/ -- IgG4-related disease (IgG4-RD ...
Medscape27d
Autoimmune Pancreatitis: What’s Really Behind Those Symptoms
AIP has two forms of involvement: Type 1 AIP, linked to immunoglobulin G4–related disease (IgG4-RD), and type 2 AIP ... extensive fibrosis, and IgG4-positive plasma cells.
Investing1mon
FDA approves Uplizna as first IgG4-RD targeted therapy
IgG4-RD is a rare, chronic inflammatory condition that can lead to fibrosis and organ damage. The approval is based on the results of the MITIGATE trial, which showed an 87% reduction in the risk of ...